| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Common stock, $0.01 par value | Sale | -$283K | -1.4K | -2.69% | $202.06 | 50.6K | Feb 26, 2025 | Direct | F1, F2 |
| transaction | ABBV | Common stock, $0.01 par value | Sale | -$970K | -4.78K | -9.45% | $202.93 | 45.8K | Feb 26, 2025 | Direct | F1, F3 |
| transaction | ABBV | Common stock, $0.01 par value | Sale | -$311K | -1.53K | -3.33% | $203.64 | 44.3K | Feb 26, 2025 | Direct | F1, F4 |
| transaction | ABBV | Common stock, $0.01 par value | Options Exercise | $2.54M | +22.2K | +50.15% | $114.36 | 66.5K | Feb 26, 2025 | Direct | |
| transaction | ABBV | Common stock, $0.01 par value | Sale | -$870K | -4.31K | -6.48% | $201.97 | 62.2K | Feb 26, 2025 | Direct | F1, F5 |
| transaction | ABBV | Common stock, $0.01 par value | Sale | -$2.65M | -13.1K | -21.02% | $202.92 | 49.1K | Feb 26, 2025 | Direct | F1, F6 |
| transaction | ABBV | Common stock, $0.01 par value | Sale | -$983K | -4.83K | -9.83% | $203.63 | 44.3K | Feb 26, 2025 | Direct | F1, F7 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Option (Right to buy) | Options Exercise | -$2.54M | -22.2K | -100% | $114.36 | 0 | Feb 26, 2025 | Common Stock | 22.2K | $114.36 | Direct | F8 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 27, 2024. |
| F2 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.58 to $202.45, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.58 to $203.56, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F4 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.58 to $203.65, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.55 to $202.48, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F6 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.55 to $203.46, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F7 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.55 to $203.68, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F8 | Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |